



דצמבר 2025

Tecentriq® 1875mg/15ml SC
atezolizumab
Solution for injection

רופא/ה יקר/ה, רוקח/ת יקר/ה,
חברת רוש פרמצבטיקה (ישראל) בע"מ מבקשת להודיעכם על מספר עדכונים שבוצעו בעלון לרופא של התכשיר טיסנטריק 1875 מ"ג/15 מ"ל תת-עורי. בהודעה זו מצוינים רק עדכונים מהותיים ועדכונים אשר מהווים החמרה.

ההתוויות הרשומות לתכשיר בישראל:

Urothelial Carcinoma

- TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumours have a PD-L1 expression $\geq 5\%$.
- TECENTRIQ is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy.

Non-Small Cell Lung Cancer

- TECENTRIQ, as monotherapy, is indicated as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on $\geq 50\%$ of tumor cells (TCs).
- TECENTRIQ, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained $\geq 50\%$ of tumor cells [TC $\geq 50\%$] or PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 10\%$ of the tumor area [IC $\geq 10\%$]), as determined by an approved test, with no EGFR or ALK genomic tumor aberrations.
- TECENTRIQ, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, TECENTRIQ, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.
- TECENTRIQ, in combination with paclitaxel protein-bound and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
- TECENTRIQ is indicated for the treatment of patients with metastatic NSCLC who are naïve to anti-PD-L1 or anti-PD-1 therapies and have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.

Locally Advanced or Metastatic Triple-Negative Breast Cancer

TECENTRIQ, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression $\geq 1\%$ and who have not received prior chemotherapy for metastatic disease.

Small Cell Lung Cancer

TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Hepatocellular Carcinoma

TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Melanoma

TECENTRIQ, in combination with cobimetinib and vemurafenib, is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Alveolar Soft Part Sarcoma

TECENTRIQ, as a single agent, is indicated for the treatment of adult patients with unresectable or metastatic alveolar soft part sarcoma (ASPS).

למידע נוסף יש לעיין בעלון לרופא כפי שנשלח למשרד הבריאות.
העלון המעודכן נשלח לפרסום במאגר התרופות שבאתר משרד הבריאות, וניתן לקבלו מודפס ע"י
פנייה לבעל הרישום: רוש פרמצבטיקה (ישראל) בע"מ, ת.ד. 6391, הוד השרון 4524079
טלפון 09-9737777. כתובתנו באינטרנט: www.roche.co.il.

ב ב ר כ ה,



לילי אדר
רוקחת ממונה



בתאור צפרי-חגג
מחלקת רישום

עדכונים מהותיים בעלון לרופא

בסעיף **Adverse Reactions** עודכן המידע הבא:

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of TECENTRIQ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- Cardiac: pericarditis, pericardial effusion, cardiac tamponade
- Musculoskeletal and Connective Tissue: tenosynovitis